GlaxoSmithKline is buying a U.S. biotechnology company that is researching resveratrol, the chemical compound found in red wine that may retard the aging process. The CEO of the company says that “drugs that mimic resveratrol, by activating enzymes called sirtuins, could ‘treat in a safe, natural new way, many of the major killers of western society.'” We can’t wait to see the commercials that GSK puts out for this one.
Glaxo Buys Aging Retardation Drug Company
By cwalters April 24, 2008
- the price of getting well Doctors Not Happy After Drug Goes From $13.50/Tablet To $750 Overnight
- Partnering for health Google, GlaxoSmithKline Partner For $715M Bioelectronic Medicines Firm
- well that's settled GSK To Pay $105 Million To Settle Advair, Paxil, Wellbutrin Disputes
- knowing the stats Pharmaceutical Companies Using Fitness Trackers To Collect Data On Drug Trials, Other Research
- return from exile Nearly A Year After Recall, Alli Weight-Loss Pills Return To Stores